

Lyzme5® Clinical Human Study

**Human Study II
Summary Report**

Study Coordinator: Jeff Golini (NIH Certified Study Coordinator)

Study Overseer: Wendy Jones, MS

Study Doctor: Dr. Stubbee, N.D.

Final Revision: May 1st, 2013

Lyzme5® Clinical Human Study Human Study II

Report Summary

Procedure

35 overweight humans were recruited for the start of this study.

No changes were made to any of the subject's diets, exercise programs or life styles.

Lyzme5® was administered as follows in a liquid form:

Week 1 1 tsp or 500 mg 20 minutes before breakfast

Week 2 1 tsp or 500 mg twice per day. Once 20 minutes before breakfast and once
20 minutes before lunch

Week 3 through Week 12 1 tsp or 500 mg three times per day. Once 20 minutes
before breakfast, once 20 minutes before lunch and once 20 minutes before dinner.

The study was to run for 12 weeks, with weigh ins at the beginning and end of study
along with blood work.

Results

The average pounds loss per participants who completed the study was 7.26 lbs. The
subject that lost the most was 24 pounds and the subject that lost the least was 1 pound.

Side Effects:

The liquid form of delivery choose for the study proved to cause some participants heart
burn do to masking oils and flavors needed to make palatable. A better delivery system
will need to be developed to prevent this like a capsule or tablet form.

Conclusion:

In this clinical study, Lyzme5® significantly lowered total body weight and proved to be
effective with minimal side effects.